A detailed history of Meeder Asset Management Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Meeder Asset Management Inc holds 82 shares of RYTM stock, worth $4,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82
Holding current value
$4,915
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$40.81 - $55.0 $3,346 - $4,510
82 New
82 $4,000
Q3 2021

Nov 08, 2021

SELL
$11.68 - $20.72 $70,991 - $125,936
-6,078 Closed
0 $0
Q2 2021

Aug 09, 2021

BUY
$18.52 - $22.55 $112,564 - $137,058
6,078 New
6,078 $119,000
Q4 2020

Feb 09, 2021

SELL
$21.17 - $32.61 $207,974 - $320,360
-9,824 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$18.13 - $30.61 $172,760 - $291,682
9,529 Added 3230.17%
9,824 $213,000
Q2 2020

Aug 11, 2020

SELL
$14.41 - $25.35 $5,173 - $9,100
-359 Reduced 54.89%
295 $7,000
Q1 2020

May 15, 2020

BUY
$13.16 - $22.9 $3,855 - $6,709
293 Added 81.16%
654 $10,000
Q4 2019

Feb 13, 2020

BUY
$19.53 - $25.5 $7,050 - $9,205
361 New
361 $8,000
Q3 2019

Oct 17, 2019

SELL
$18.62 - $24.51 $1,415 - $1,862
-76 Closed
0 $0
Q2 2019

Aug 05, 2019

BUY
$21.11 - $28.48 $1,604 - $2,164
76 New
76 $2,000
Q1 2019

Apr 16, 2019

SELL
$24.76 - $31.66 $14,435 - $18,457
-583 Closed
0 $0
Q4 2018

Jan 17, 2019

SELL
$24.11 - $31.34 $2,001 - $2,601
-83 Reduced 12.46%
583 $16,000
Q3 2018

Nov 02, 2018

BUY
$26.99 - $35.85 $12,415 - $16,491
460 Added 223.3%
666 $0
Q2 2018

Jul 24, 2018

BUY
$17.02 - $35.2 $3,506 - $7,251
206 New
206 $0
Q1 2018

May 03, 2018

SELL
$19.9 - $32.25 $4,477 - $7,256
-225 Closed
0 $0
Q4 2017

Feb 02, 2018

BUY
$22.0 - $30.51 $4,950 - $6,864
225
225 $6,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.34B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.